Axa
CFRX

Axa’s ContraFect Corporation CFRX Stock Holding History

Axa’s Portfolio CFRX Stock Details CFRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,081
Closed -$2.55M – 1424
2018
Q4 		$2.55M Hold
2,081
– – 0.01% 773
2018
Q3 		$3.45M Buy
2,081
+1,378
+196% +$2.28M 0.01% 760
2018
Q2 		$1.24M Buy
+703
New +$1.04M ﹤0.01% 954

Other funds holding CFRX

FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $355M AUM 45.63% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Axa's CFRX Position: Q1 2019 in Review

Axa sold out of ContraFect Corporation (CFRX) in Q1 2019, closing a stake of 2,081 shares — an estimated $2.55M sold.

Axa first reported a position in CFRX in Q2 2018 and held it in 3 quarters. The position peaked at $3.45M in Q3 2018. 37 funds tracked by Wall St. Rank hold CFRX as of Q1 2019.

  • Axa reported no remaining ContraFect Corporation position as of Q1 2019 after selling out during the quarter.
  • Axa sold 2,081 ContraFect Corporation shares in Q1 2019, an estimated $2.55M.
  • Axa first reported a position in ContraFect Corporation in Q2 2018 and held it in 3 quarters.
  • Axa's ContraFect Corporation position peaked at $3.45M in Q3 2018.
  • 37 funds tracked by Wall St. Rank held ContraFect Corporation as of Q1 2019.

Based on Axa's 13F filing for Q1 2019, filed 14 May 2019.